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Abstract Recombinant human granulocyte colony-
stimulating factor (filgrastim) has multiple hematologic and
oncologic indications as Neupogen® (Amgen filgrastim).
Hospira has developed a biosimilar filgrastim (Nivestim™).
Here, results are reported from a phase I trial, primarily
designed to compare the pharmacokinetic profiles of Hospira
filgrastim and Amgen filgrastim. A phase I, single-center,
open-label, randomized trial was undertaken to demonstrate
equivalence of the pharmacokinetic characteristics of Hospira
filgrastim and Amgen filgrastim. Forty-eight healthy volun-
teers were randomized to receive intravenous (i.v.) or
subcutaneous (s.c.) dosing and then further randomized to
order of treatment. Volunteers in each of the two dosing
groups received a single 10µg/kg dose of Hospira filgrastim
or Amgen filgrastim, with subsequent crossover. Bioequiva-
lence was evaluated by analysis of variance; if the estimated
90% confidence intervals (CIs) for the ratio of ‘test’ to
‘reference’ treatment means were within the conventional
equivalence limits of 0.80–1.25, then bioequivalence was
concluded. Forty-six volunteers completed the study. Geo-
metric mean area under the curve from time 0 to the last time
point (primary endpoint) was similar in volunteers given
Hospira filgrastim or Amgen filgrastim following i.v. (ratio of
means: 0.96; 90% CI: 0.90–1.02) or s.c. (ratio of means: 1.02;
90% CI: 0.95–1.09) dosing; 90% CIs were within the
predefined range necessary to demonstrate bioequivalence.
Hospira filgrastimwas welltoleratedwithnoadditionalsafety
concerns over Amgen filgrastim. Hospira filgrastim is
bioequivalent with Amgen filgrastim in terms of its pharma-
cokinetic properties and may provide a clinically effective
alternative.
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Introduction
Granulocyte colony-stimulating factor (G-CSF) is a natu-
rally occurring cytokine that stimulates the proliferation and
differentiation of hematopoietic stem and progenitor cells
committed to the neutrophil and granulocyte lineages. Fully
differentiated neutrophilic granulocytes are functionally
a c t i v a t e db yG - C S F[ 1–4]. Due to its hematopoietic
activity, recombinant G-CSF (filgrastim) is used as an
integral part of supportive therapy across multiple indica-
tions under the trade name Neupogen® (Amgen filgrastim;
Amgen Inc., Thousand Oaks, CA, USA) [5–7]. In the
oncology setting, Amgen filgrastim is licensed for use in
patients with non-myeloid malignancies who are receiving
myelosuppressive cytotoxic chemotherapy [8]. In these
patients, Amgen filgrastim has been shown to significantly
reduce the incidence, severity and duration of severe
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DOI 10.1007/s00277-010-0961-xneutropenia and febrile neutropenia, and decrease the rate of
infections compared with chemotherapy alone [5, 6, 9–14].
Other indications of Amgen filgrastim include the mobiliza-
tion of peripheral blood progenitor cells, and the treatment of
severe congenital, cyclic or idiopathic neutropenia [8].
Following the patent expiry of Amgen filgrastim in
2006, Hospira has developed a biosimilar version of
filgrastim (Hospira filgrastim, Nivestim™), which could
potentially provide a clinically effective alternative to
Amgen filgrastim. Owing to the complex nature of the
manufacturing process of biopharmaceuticals, and the
potential for heterogeneity between reference products and
biosimilar medicines, guidelines are in place for the
development of biosimilars in terms of quality, safety, and
efficacy [15]. In accordance with these guidelines, the
similarity of Hospira filgrastim and Amgen filgrastim with
respect to their physicochemical profile was demonstrated
using a wide range of rigorous analytical techniques [16].
Further to this, we report results from a randomized phase I
trial primarily designed to compare the pharmacokinetic
(PK) profile of Hospira filgrastim with that of Amgen
filgrastim following administration of a single intravenous
(i.v.) or subcutaneous (s.c.) dose in healthy volunteers.
Pharmacodynamic (PD) and safety assessments were
secondary objectives. This is the first of two studies: a
second phase I study primarily designed to compare the PD
profile of Hospira filgrastim with that of Amgen filgrastim
will also be reported in this journal (Annals of Hematology
in press).
Design and methods
Eligibility
The study protocol and all amendments were approved by a
local research ethics committee and the UK Medicines and
Healthcare products Regulatory Agency. All volunteers
gave written informed consent before any study-specific
procedures were undertaken. Volunteers were free to
withdraw from the study at any time.
Healthy, non-smoking, male or female volunteers aged
18–45 were recruited. All volunteers were required to
have a body mass index of 19–30 kg/m
2 and a body
weight of 50–100 kg. Volunteers with clinically significant
symptoms, pathologic laboratory findings, vital signs or
12-lead electrocardiogram (ECG) results were excluded
from the study. Additional exclusion criteria included: a
positive test for human immunodeficiency virus or
hepatitis; a history of pulmonary infiltrates or pneumonia
in the previous 6 months; a history or evidence of drug or
alcohol abuse; hereditary fructose intolerance; a history of
hypotensive episodes associated with i.v. drug adminis-
tration; blood donation ≥500 ml in the previous 12 weeks;
and pregnancy or lactation. Concurrent use of prescription
or over-the-counter medicines (excluding hormonal con-
traceptives and occasional use of paracetamol) was not
permitted. Similarly, caffeine- and alcohol-containing
beverages were not allowed during the assessment periods
or in the 24 h prior to first dose.
Study design and outcomes
Volunteers were treated at Charles River Clinical Services,
Edinburgh, UK, between October 18 and December 28,
2006, as part of a randomized, comparator-controlled, two-
way crossover trial (Fig. 1). Volunteers were randomized to
one of two parallel groups (i.v. or s.c. routes), then further
randomized to order of agent administration. Study drugs
were administered on an open-label basis. Volunteers in
each of the two parallel groups received a single 10-µg/kg
dose of Hospira filgrastim and Amgen filgrastim in random
order. Randomization was performed according to a
computer-generated randomization list, produced by
Constella Group Ltd, Abingdon, UK. Conditions relating
to provision of meals, fasting periods, overnight stays, and
levels of permitted physical activity were standardized
throughout.
An initial screening period of up to 21 days was
followed by two 6-day assessment periods, separated by a
washout period of at least 13 days. Hospira filgrastim and
Amgen filgrastim were administered via s.c. injection or via
i.v. infusion over 30 min.
The primary endpoint was the area under the curve from
time 0 to the last time point (AUC0–tlast) for plasma G-CSF
concentration. Secondary PK endpoints were: maximum
observed plasma concentration of G-CSF (Cmax); time at
which Cmax occurred (Tmax); elimination half life (T1/2);
AUC from time 0 extrapolated to infinity (AUC0–infinity);
terminal elimination rate constant (λz); and clearance.
Secondary PD endpoints included ANC AUC0–tlast, ANC
Tmax, ANCmax, and ANCmin. Safety was also assessed as a
secondary endpoint.
Blood samples were collected for measurement of
plasma G-CSF at −1, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10,
12, 16, 24, and 48 h post dose. Samples were also collected
at −1, 0.5, 1, 2, 4, 6, 8, 24, 48, 72, 96, and 120 h following
dose administration for PD (ANC) analysis. G-CSF
concentrations were assessed by the Charles River Labora-
tories Central Laboratory using a validated commercial
assay [17–21].
Safety was assessed based on observed adverse
events (AEs), clinical laboratory tests (hematology,
biochemistry and urinalysis), physical examination,
results of 12-lead and 30-min continuous ECG and
vital sign assessments.
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The PK population consisted of all volunteers who
completed the study with a sufficient number of quantifi-
able concentrations to warrant parameter estimation in both
assessment periods. The PD population consisted of all
volunteers for whom an evaluable PD parameter was
obtained in both assessment periods. The safety population
comprised all volunteers who received at least one dose of
study medication.
Tmax λz, clearance for plasma concentration of G-CSF
and ANC Tmax were summarized descriptively only. All
other PK and PD parameters were loge-transformed prior to
statistical analysis and presented as geometric means, along
with other summary statistics. Missing concentrations were
deleted, resulting in an interpolation between the nearest
two values. Outliers were identified using an outlier check
(Dixon test or T procedure). PK data were analyzed by non-
compartmental methods using WinNonlin® (Pharsight®
Corporation, Mountain View, CA, USA).
Bioequivalence was assessed for the primary and
secondary endpoints using a mixed effects analysis of
variance, with terms including subject within sequence as a
random effect, and study drug and period as fixed effects. A
90% confidence interval (CI) for the ratio of ‘test’ to
‘reference’ means was calculated using least squares
estimates of the means and residual variance from the
model. If the 90% CI was completely within the conven-
tional bioequivalence limits of 0.80–1.25, then bioequiva-
lence could be concluded.
A total of 44 evaluable volunteers were required for 80%
power (α=0.05) to demonstrate bioequivalence between
Hospira filgrastim and Amgen filgrastim, assuming a
within-subject coefficient of variation of 21% (i.v. volun-
teers) or 23% (s.c. volunteers) and a bioequivalence range
of 0.80–1.25 in the ‘test’ to ’reference’ mean ratio for
AUC0–tlast.
Results
Subject disposition
Forty-eight volunteers were enrolled: 22 into the i.v. group
and 26 into the s.c. group (Fig. 1). Two volunteers in the
i.v. group withdrew from the study owing to AEs (moderate
nausea, dizziness, agitation, pharynx dysesthesia, dyspnea,
and a respiratory disorder) and withdrawal of consent,
respectively, after receiving a single dose of Amgen
filgrastim. These volunteers were excluded from the PK
and PD analyses. Three additional volunteers in the i.v.
group were excluded from the PD analyses due to
insufficient data (one subject had three missing values in
a row due to discontinuation, two volunteers did not
complete both assessment periods). During review of the
PD data, it was noted that there were two consecutive
missing ANC results for five volunteers (two in the i.v.
group and three in the s.c. group). Therefore, for these
patients, ANC estimates were interpolated from the nearest
two known ANC values. All volunteers were evaluable for
safety.
Investigators permitted several volunteers to take para-
cetamol for pain relief during the study; however, this was
not considered to affect the study outcomes and therefore
Fig. 1 Study design and volun-
teer disposition. (a) All volun-
teers who received ≥1 dose of
study medication; (b) all volun-
teers who completed the study
with a sufficient number of
quantifiable concentrations to
warrant parameter estimation in
both assessment periods; (c) all
volunteers for whom an evalu-
able PD parameter was obtained
in both assessment periods
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were generally well matched between groups (Table 1).
Pharmacokinetics
The primary PK endpoint (geometric mean AUC0–tlast) was
similar in volunteers given Hospira filgrastim or Amgen
filgrastim following either i.v. (ratio of means, 0.96; 90%
CI, 0.90–1.02) or s.c. (ratio of means, 1.02; 90% CI, 0.95–
1.09) administration (Table 2). For both routes of admin-
istration, 90% CIs were within the predefined range of
0.80–1.25 necessary to demonstrate bioequivalence of the
two agents. In volunteers who received Hospira filgrastim
or Amgen filgrastim via the s.c. route, the geometric mean
AUC0–tlast was slightly lower than in those who received
study medication via the i.v. route (ratio of means: 0.75;
90% CI: 0.67–0.84). Analysis of secondary PK parameters
showed that geometric means for AUC0–infinity, Cmax, T1/2,
Tmax, λz, and clearance were similar in volunteers who
received Hospira filgrastim or Amgen filgrastim following
either i.v. or s.c. administration (Table 2). As with the
primary endpoint, 90% CIs for AUC0–tlast, Cmax, and T1/2
were within the predefined range required to demonstrate
bioequivalence of the two agents, irrespective of adminis-
tration route.
Pharmacodynamics
The PD parameters analyzed were generally similar in
volunteers given Hospira filgrastim or Amgen filgrastim, in
both the s.c. and i.v. groups. In the i.v. group, the ratios of
geometric means for ANC AUC0–tlast, ANCmax and
ANCmin were 1.03 (90% CI, 0.99–1.08), 1.07 (90% CI,
1.00–1.14), and 0.83 (90% CI, 0.68–1.02), respectively.
The 90% CIs for AUC0–tlast and ANCmax were within the
range required to show bioequivalence of Hospira filgras-
tim and Amgen filgrastim, while those for ANCmin were
outside the equivalence range. Mean values for ANC Tmax
were similar in volunteers who received i.v. Hospira
filgrastim or i.v. Amgen filgrastim (17.99 vs. 19.05 h,
respectively).
Similar results were obtained in the s.c. group, with
geometric mean ratios of 1.03 (90% CI: 0.99–1.06), 1.04
(90% CI: 0.98–1 . 1 1 ) ,a n d1 . 1 3( 9 0 %C I :0 . 8 3 –1.54)
reported for ANC AUC0–tlast, ANCmax, and ANCmin,
respectively. As in the i.v. group, s.c. Hospira filgrastim
and s.c. Amgen filgrastim were shown to be bioequivalent
for ANC AUC0–tlast and ANCmax, but not for ANCmin.
MeanANCTmax was 19.44 h in volunteers who received s.c.
Hospira filgrastim and 21.49 h in those who received s.c.
Amgen filgrastim.
Safety
The overall incidence of AEs was lower in volunteers who
received i.v. Hospira filgrastim compared with those who
received i.v. Amgen filgrastim (60 vs. 82%, respectively),
whereas it was similar in volunteers who received study
drugs via the s.c. route (77% vs. 73%, respectively;
Table 3). This pattern was also reflected in the incidence
of AEs related to the study drug (50% vs. 68%,
respectively, for the i.v. route; 58% vs. 50%, respectively,
for the s.c. route).
The most common AEs were headache, back pain and
nausea (Table 3), which were generally related to the study
drug. Only minor differences in AE profiles were observed
between Hospira filgrastim and Amgen filgrastim (Table 3).
All AEs were mild or moderate in intensity and no serious
AEs were reported.
No clinically significant changes in heart rate, 12-lead
ECG, hematology, biochemistry, urinalysis, and physical
examination were reported.
Discussion
Guidance issued by the European Medicines Agency
(EMEA) states that new biosimilar medicinal products
containing filgrastim should demonstrate comparability
with the reference product, Amgen filgrastim [15]. The
EMEA recommends that extensive preclinical and clinical
studies are conducted, including PK, PD and safety
investigations. PK investigations should include single-
dose, crossover trials of s.c. and i.v. administration, with
AUC as the primary endpoint, and Cmax and T1/2 as
secondary parameters. The phase I PK study reported here
was designed in accordance with these guidelines and
forms part of the regulatory assessment for Hospira
filgrastim.
Table 1 Baseline demographics
Variable i.v. route s.c. route
(n=22) (n=26)
Male gender, n (%) 10 (45.5) 10 (38.5)
Mean age, years (SD) 30.6 (9.3) 30.7 (7.6)
Ethnicity, n (%)
Caucasian 20 (90.9) 25 (96.2)
Black 0 (0) 0 (0)
Asian 1 (4.5) 1 (3.8)
Other 1 (4.5) 0 (0)
Mean height, cm (SD) 171.2 (7.7) 168.8 (7.7)
Mean weight, kg (SD) 72.4 (8.8) 70.2 (10.8)
Mean BMI, kg/m
2 (SD) 24.8 (3.1) 24.6 (3.1)
SD standard deviation, BMI body mass index
930 Ann Hematol (2010) 89:927–933All PK parameters examined were found to be similar
following a single dose of Hospira filgrastim or Amgen
filgrastim, irrespective of dosing route (i.v. or s.c.).
Importantly, therapeutic bioequivalence was demonstrated
for AUC0–tlast (primary endpoint), AUC0–infinity, Cmax, and
T1/2 with i.v. or s.c. dosing. As reported previously for
G-CSF [22], the bioavailability of Hospira filgrastim and
Amgen filgrastim was higher when administered via the i.v.
versus the s.c. route.
The two drugs were also shown to be bioequivalent for
all PD parameters except ANCmin, regardless of the
administration route. There was some slight variation in
Tmax between the two drugs, but these minor differences are
unlikely to be of clinical importance and, overall, the data
overwhelmingly support the bioequivalence of Hospira
filgrastim and Amgen filgrastim. This observed bioequiva-
lence is likely to be attributed to the almost identical
physicochemical (including formulation, strength, compo-
Table 2 Summary of PK data
PK parameter Geometric mean (range) Ratio 90% CI
Hospira filgrastim Amgen filgrastim
i.v. route (n=20)
AUC0–tlast, pg.hour/ml 1,259,808 (827,253–1,882,329) 1,316,067 (914,165–1,864,730) 0.96 0.90–1.02
a
Cmax, pg/ml 288,450 (194,944–479,154) 305,687 (198,410–935,835) 0.94 0.84–1.07
a
Tmax, hours 0.62 (0.50–1.00) 0.71 (0.50–3.00) ––
T1/2, hours 7.57 (3.22–15.37) 8.06 (3.36–13.68) 0.95 0.81–1.12
a
AUC0–infinity, pg.hour/ml 1,264,255 (832,227–1,888,906) 1,319,602 (916,022–1,868,352) 0.96 0.91–1.02
a
λz 0.092 (0.045–0.216) 0.086 (0.051–0.206) ––
Clearance, ml/hour/kg 7.910 (5.294–12.016) 7.578 (5.352–10.917) ––
s.c. route (n=26)
AUC0–tlast, pg.hour/ml 946,611 (426,566–1,340,753) 929,670 (671,388–1,248,375) 1.02 0.95–1.09
a
Cmax, pg/ml 94,765 (49,602–159,675) 90,754 (62,633–119,410) 1.04 0.97–1.13
a
Tmax, hours 5.11 (3.00–8.00) 5.06 (3.05–8.00) ––
T1/2, hours 7.01 (5.29–11.26) 6.91 (5.30–9.98) 1.01 0.94–1.09
a
AUC0–infinity, pg.hour/ml 950,955 (427,687–1,344,385) 933,847 (676,427–1,252,249) 1.02 0.95–1.09
a
λz 0.099 (0.062–1.131) 0.100 (0.069–1.131) ––
Clearance, ml/hour/kg 10.516 (7.438–23.382) 10.708 (7.986–14.784) ––
– not reported.
aThe 90% CI was within the predefined equivalence range of 0.80–1.25, demonstrating bioequivalence between the two agents
Table 3 Treatment-emergent AEs occurring in >5 volunteers across all treatment groups
AE i.v. route, n (%) s.c. route, n (%)
Hospira filgrastim
(n=20)
Amgen filgrastim
(n=22)
Hospira filgrastim
(n=26)
Amgen filgrastim
(n=26)
Any event 12 (60.0) 18 (81.8) 20 (76.9) 19 (73.1)
Gastrointestinal disorders 2 (10.0) 7 (31.8) 4 (15.4) 4 (15.4)
Nausea 0 (0) 4 (18.2) 4 (15.4) 3 (11.5)
General disorders and administration site
conditions
1 (5.0) 3 (13.6) 4 (15.4) 1 (3.8)
Musculoskeletal and connective tissue
disorders
7 (35.0) 6 (27.3) 12 (46.2) 10 (38.5)
Back pain 2 (10.0) 2 (9.1) 9 (34.6) 9 (34.6)
Nervous system disorders 5 (25.0) 9 (40.9) 7 (26.9) 9 (34.6)
Headache 5 (25.0) 8 (36.4) 7 (26.9) 8 (30.8)
Respiratory, thoracic and mediastinal
disorders
3 (15.0) 2 (9.1) 5 (19.2) 2 (7.7)
Ann Hematol (2010) 89:927–933 931sition, purity, and presentation) and molecular characteristics
of the two drugs [16].
Hospira filgrastim was well tolerated and there were no
unexpected safety concerns associated with its use. The AE
profiles of Hospira filgrastim and Amgen filgrastim, in
terms of their nature and intensity, were comparable, and
similar to those reported previously for recombinant G-CSF
in healthy volunteers [23].
This study, together with a second phase I study
(also reported in this journal) (Annals of Hematology in
press), provide a comprehensive analysis of the PK and
PD characteristics of Hospira filgrastim. Similar analy-
ses have been described in the literature for the
biosimilar filgrastim XM02, although fewer endpoints
were reported [24]. Taken together, the two phase I
characterization studies provide a strong rationale for the
further clinical evaluation of Hospira filgrastim. In this
regard, a large, randomized, double-blind, phase III trial of
Hospira filgrastim versus Amgen filgrastim (5 µg/kg s.c.)
in patients with breast cancer receiving myelosuppressive
chemotherapy has been conducted [25]. Overall, data
suggest that Hospira filgrastim is effective and well
tolerated, and may provide an alternative to Amgen
filgrastim for the treatment of chemotherapy-induced
neutropenia and other indications for which G-CSF is
routinely used.
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